![](images/soligenixbanner.jpg)
News Releases
View all Historical Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 20, 2016Supported with NIAID Contract Funding of up to $24.7 million
Princeton, NJ – December 20, 2016 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Dec 16, 2016
Princeton, NJ, December 16, 2016 – Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is...
-
Dec 13, 2016
Princeton, NJ, December 13, 2016 – Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is...
-
Dec 12, 2016
Princeton, NJ – December 12, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Dec 8, 2016Friday, December 16, 2016, from 8:30-9:30 am ET
Princeton, NJ – December 8, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...